Gilead Expands oncology portfolio with $5bn Tubulis deal
Listed American biopharmaceutical company Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a privately held German biotechnology company, for a total potential consideration of $5bn. Under the terms of the deal, Gilead will provide an upfront cash payment of $3.15bn, with an additional $1.85bn tied to future contingent milestones. The transaction is expected to close in the…
Competition authority green lights €12bn Aedifica and Cofinimmo merger
The merger between Belgian listed real estate company Aedifica and rival Cofinimmo reached a definitive milestone on January 21, marking the likely creation of Europe’s largest listed healthcare REIT with a combined portfolio exceeding €12.1bn. Following a period of delay that pushed the timeline back by approximately three months, the Belgian Competition Authority has officially cleared the path for the…
Optimed bought by listed Hong Kong company
Optimed Medizinische Instrumente, the Germany-based specialist in minimally invasive therapy devices, is being bought by Hong Kong listed medical technology firm Zylox-Tonbridge. The acquisition signals a major shift as the acquirer transitions into a truly multinational medical technology entity with a strengthened presence in Europe. The definitive agreement to acquire, announced on January 16, marks a defining milestone in the…